Salix Pharmaceuticals, Ltd. Stock

Stocks

15-03-16	Endo : Valeant trumps Endo with $10.96 billion bid for Salix Pharma	RE
15-03-16	Bank of Montreal : TSX climbs on upbeat sentiment ahead of Fed meeting	RE
15-03-16	Wall St. bounces as dollar drops, Fed worries ease	RE
15-03-16	Endo : withdraws offer for Salix	RE
15-03-11	Valeant Pharmaceuticals Intl : TSX rebounds as energy shares advance with oil price	RE
15-03-05	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
15-03-05	AbbVie : Biotech buys get pharma M&A off to flying start in 2015	RE
15-03-05	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
15-02-24	Shire : buys Meritage Pharma for at least $70 million	RE
15-02-23	Canadian Natural Resources : TSX gains on Valeant news; financial stocks weigh	RE
15-02-23	Boeing : Nasdaq ends up 9th session; S&P 500, Dow dip with energy	RE
15-02-23	BioMarin Pharmaceutical : Exclusive - Rare disease drugmaker PTC Therapeutics explores sale: sources	RE
15-02-21	Salix Pharmaceuticals : Valeant nears deal to buy Salix for about $10 billion - WSJ	RE

15-03-11	Salix Pharmaceuticals : Confirms Receipt of an Unsolicited Proposal from Endo International plc	BU
15-03-02	Salix Pharmaceuticals : Reports 4Q2014 and FY2014 Results	BU
15-02-28	Salix Pharmaceuticals : SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Salix Pharmaceuticals, Ltd. And Encourages Investors To Contact The Firm For Additional Information	BU
15-02-27	Salix Pharmaceuticals : Stockholders Encouraged to Contact Securities Law Firm about Takeover	PR
15-02-26	SALIX PHARMACEUTICALS : SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout	BU

15-04-01	Valeant Pharmaceuticals Intl : Le laboratoire canadien Valeant conclut l'acquisition de Salix
15-03-30	Sanofi ne juge pas des acquisitions "indispensables"-Pdt
15-03-16	Le recul du dollar a favorisé le rebond de Wall Street
15-03-16	Allergan : Valeant relève son offre sur Salix, Endo jette l'éponge
15-03-16	BlackBerry : Les valeurs à suivre sur les marchés américains

Manager	Title	Age	Since
Josh Coyle SAM	Sales & Marketing	-	2017-12-31
John Temperato SAM	Sales & Marketing	61	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SALIX PHARMACEUTICALS, LTD.	-.--%	+0.16%	-	-	0
MERCK & CO., INC.	+0.81%	+4.40%	+56.82%	+23.96%	326B
HALOZYME THERAPEUTICS, INC.	+2.41%	+6.16%	+44.54%	+91.12%	9.9B
KYOWA KIRIN CO., LTD.	+1.77%	+2.89%	+4.65%	-0.48%	8.49B
SK BIOPHARMACEUTICALS CO., LTD.	-2.93%	+2.45%	-20.66%	-2.69%	4.28B
BETTA PHARMACEUTICALS CO., LTD.	-3.73%	-3.89%	-9.31%	+1.86%	3.61B
YUHAN CORPORATION	-1.81%	+1.58%	-41.23%	+7.12%	3.63B
SUPERNUS PHARMACEUTICALS, INC.	+1.60%	-0.29%	+42.86%	+56.90%	2.77B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-0.87%	-4.54%	-7.97%	-10.77%	2.1B
SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD.	-5.16%	-6.21%	-20.06%	+18.69%	1.78B
Average	-0.79%	+0.00%	+5.52%	+20.63%	40.24B
Weighted average by Cap.	+0.73%	+4.70%	+51.84%	+24.54%

Employees

Sector